Publications by authors named "Paulo Lisboa Bittencourt"

Background And Aim: Primary sclerosing cholangitis (PSC) has been shown to recur after liver transplantation (LT). Some studies have identified certain clinical and laboratory variables associated with an increased risk for recurrent PSC (rPSC) in Caucasians. Furthermore, de novo cholangiocarcinoma (CCA) has been reported anecdotally in patients with rPSC.

View Article and Find Full Text PDF

Objective: Primary biliary cholangitis is a chronic and progressive autoimmune liver disease, whose prognosis can be improved by normalizing alkaline phosphatase and bilirubin. While ursodeoxycholic acid (UDCA) is first line standard of care, approximately 40 % of patients exhibit incomplete response. We aimed to identify prognostic markers for deep response to UDCA therapy at presentation.

View Article and Find Full Text PDF

Background: Chronic excessive use of alcohol is an important risk factor for several health and social conditions.

Methods: A cross-sectional survey, in a sample representative of the Brazilian population,was conducted to evaluate the frequency of consumption of alcoholic beverages and behaviors concerning liver diseases. Participants were prospectively interviewed using a questionnaire regarding alcohol consumption and actions toward liver health.

View Article and Find Full Text PDF

Backgrounds: COVID-19 pandemic led to a sharp decline in surgical volume worldwide due to the postponement of elective procedures. This study evaluated the impact of COVID-19 pandemic in surgical volumes and outcomes of abdominal surgery in high-risk patients requiring intensive care unit admission.

Methods: patients admitted for postoperative care were retrospectively evaluated.

View Article and Find Full Text PDF

Background: Tacrolimus is the primary calcineurin inhibitor used in immunosuppressive regimens to prevent allograft rejection (AR) after organ transplantation. Recent studies have linked intrapatient variability (IPV) of tacrolimus with AR occurrence and reduced survival, especially in kidney transplant recipients. However, limited data are available on the impact of tacrolimus IPV on adverse outcomes after liver transplantation (LT).

View Article and Find Full Text PDF

Background: Ursodeoxycholic acid (UDCA) is the standard treatment for primary biliary cholangitis (PBC), but a significant proportion of patients do not respond adequately, leading to increased risk of adverse outcomes. This study aims to develop a new and straightforward predictive score to identify PBC patients likely to achieve a complete response to UDCA.

Methods: A logistic regression analysis was conducted using a derivation cohort of PBC patients to identify pre-treatment variables associated with response to UDCA.

View Article and Find Full Text PDF

Background: Clinical features and outcomes of patients admitted to the intensive care unit due to acute abdomen are important to be investigated.

Aims: To evaluate the outcomes of critically ill subjects with acute abdomen according to etiology, comorbidity and severity.

Methods: Outcomes of 1,523 patients (878 women, mean age 66±18 years) consecutively admitted to a specialized gastrointestinal intensive care unit with different causes of acute abdomen from January 2012 to December 2019, were retrospectively evaluated according to etiology, comorbidity and severity.

View Article and Find Full Text PDF
Article Synopsis
  • Tacrolimus (Tac) is the most frequently used calcineurin-inhibitor in solid organ transplants, particularly kidney transplants, but has shown high intra-patient variability (IPV) that raises concerns for graft rejection and poor outcomes.
  • There is limited research on the effects of high Tac IPV on non-kidney transplants and ongoing debate about its actual impact on graft and patient survival in kidney transplants, partly because of differing study methodologies and time frames.
  • Further investigation is needed to understand the implications of high Tac IPV on various transplant outcomes (kidney, liver, heart, lung, pancreas) to inform better clinical practices.
View Article and Find Full Text PDF

Background: Little is known about the knowledge of the Brazilian population regarding prevention/screening/diagnosis of cirrhosis and hepatocellular carcinoma (HCC). We aimed to investigate the public knowledge/attitudes toward liver diseases in Brazil.

Methods: A cross-sectional survey was conducted in which 1.

View Article and Find Full Text PDF

Background: Several HCV patients in Brazil were lost to follow-up (LTFU) in the last two decades before achievement of sustained virological response (SVR). Strategies to recall those diagnosed but untreated patients have been used elsewhere with different success rates.

Aim: To identify and retrieve LTFU patients in order to offer them the treatment with the current highly effective direct acting antiviral agents (DAAs).

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2020 the updated recommendations for the diagnosis and treatment of HCC. Since then, new data have emerged in the literature, including new drugs approved for the systemic treatment of HCC that were not available at the time.

View Article and Find Full Text PDF
Article Synopsis
  • PBC and AIH/PBC are linked to an increased risk of hepatocellular carcinoma (HCC) and extra-hepatic malignancy (EHM), prompting a study to identify cancer risk factors in these patients.
  • The study analyzed data from 752 PBC patients, finding 87 cancer cases, including 20 HCC and 67 EHM, with notable associations between HCC and factors like cirrhosis, smoking, and certain medications.
  • Cirrhosis, obesity, and past azathioprine therapy were identified as independent risk factors for HCC, while Sjogren syndrome and psoriasis correlated with EHM; overall, EHM prevalence was higher in PBC patients compared to HCC.
View Article and Find Full Text PDF

Background: Little is known about the significance of liver function tests (LFT) abnormalities in COVID-19 and their impact on disease outcomes. The aims of the study were to evaluate abnormalities of LFT in patients with COVID-19 and their impact on disease severity, mortality, and correlation with leukocyte markers of inflammation.

Methods: All patients with COVID-19 admitted to the emergency department (ED) of a single reference center were retrospectively evaluated.

View Article and Find Full Text PDF

Objective: Brazil ranks second in gross numbers of kidney and liver transplantations, but deceased organ donation is still far below the national demand for organs. Apart from a high family refusal rate, another significant barrier is healthcare workers' inappropriate knowledge concerning organ donation and transplantation. Since most of them have recently graduated from university, this study aimed to evaluate the awareness and attitudes of medical students concerning organ donation.

View Article and Find Full Text PDF

Leukocyte biomarkers, including the neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte-(MLR), platelet-to-lymphocyte (PLR) ratios and systemic immune-inflammation index (SII) have been associated with severity and mortality of patients with COVID-19. The purpose of this study was to evaluate the association of baseline leukocyte biomarkers calculated in the emergency department (ED) with the disease severity and mortality. This was a retrospective cohort study that evaluated 1,535 (mean age 57+18 years) patients with SARS-CoV-2 infection in the ED of a single reference center.

View Article and Find Full Text PDF

Introduction And Objectives: The Choosing Wisely (CW) initiative aims to improve daily practice supported by evidence concerning unnecessary medical tests, procedures, and treatments. This philosophy is essential in managing viral hepatitis (VH), which primary care physicians increasingly carry out. It is also essential to achieving disease elimination.

View Article and Find Full Text PDF

Mortality in cirrhosis is mostly associated with the development of clinical decompensation, characterized by ascites, hepatic encephalopathy, variceal bleeding, or jaundice. Therefore, it is important to prevent and manage such complications. Traditionally, the pathophysiology of decompensated cirrhosis was explained by the peripheral arterial vasodilation hypothesis, but it is currently understood that decompensation might also be driven by a systemic inflammatory state (the systemic inflammation hypothesis).

View Article and Find Full Text PDF

Background: Pre-eclampsia (PE) and eclampsia (E) are among the leading causes of maternal and fetal morbidity and mortality. Both are associated with an evolving spectrum of liver disorders.

Objective: The aim of this study was to evaluate the frequency and severity of liver involvement in pregnant women admitted to an intensive care unit with PE/E and to assess its influence on adverse maternal and fetal outcomes.

View Article and Find Full Text PDF

Background: Response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has been traditionally assessed 1 to 2 years after treatment initiation. With the development of new drugs, some patients may benefit from an earlier introduction of second-line therapies.

Aims: This study aims to identify whether well-validated response criteria could correctly identify individuals likely to benefit from add-on second-line therapy at 6 months.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of retreatment for hepatitis C in patients who did not respond to previous direct antiviral agents (DAA), highlighting Brazil's adherence to updated health guidelines.
  • The survey gathered clinical and epidemiological data from institutions nationwide, focusing on those previously treated with interferon-free regimens.
  • Results showed a 94.6% sustained virological response rate in patients retreated, indicating that the available retreatment options in Brazil are both effective and safe, supporting efforts to eliminate hepatitis C.
View Article and Find Full Text PDF